Table 3.
Selection of ligands for tumor-associated myeloid cell targeting, with the corresponding receptors.
| Liganda | Receptorsa | Nanoparticles | Cellular modelb | References |
|---|---|---|---|---|
| Anti-PD-L1 antibody | PD-L1 | Liposome |
In vitro (GL261 and TAMs generated form CT2A and GL261 culture medium) Ex vivo (TAMs isolated from primary tumor or orthotopic GL261) In vivo (Orthotopic GL261 + TAMs / IT) |
(91) |
| Cross-talk between macrophages (carrier) and GBM cells (target) | Diamond |
In vitro (histiocytic lymphoma U937 cells) In vivo (Orthotopic U87-MG and GL261 + allograft mouse bone marrow-derived macrophages / IV) |
(92) | |
| (NOX-E36) CCL2 inhibitor | CCL2 | NOX-E36 (PEGylated active agent) |
In vitro (U87-MG/CCL2+ and LN18/CCL2+) In vivo (Orthotopic U87-MG/ CCL2+ / IP) |
(93) |
The nature of nanoparticles as well as the type of preclinical studies and the cellular models are also reported.
a
PD-L1, programmed death protein 1; CCL2: chemokine ligand.
b
TAMs, tumor-associated macrophages; IT, intratumoral; IV, intravenous; IP, intraperitoneal.